Compare AngloGold Ashanti Limited (AU) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Moderna, Inc. — how do they compare? AngloGold Ashanti Limited trades at $101.64 (market cap $49.28B), while Moderna, Inc. trades at $60.26 (market cap $24.18B). The key difference: AngloGold Ashanti Limited is far larger — about 2× Moderna, Inc.'s market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AU | MRNA | |
|---|---|---|
Market Cap | $49.28B | $24.18B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $81.80 |
52-Week Low | $52.15 | $22.36 |
Enterprise Value | $48.29B | $20.33B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
